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Lisdexamfetamine Dimesylate:
A Pro drug Stimulant for





(ADHD) is a highly genetic neuropsychiatric
disorder that can cause impairment at school,
work, home, and in social relationships. Once
considered a childhood disorder, as many as
65% of children with ADHD continue to exhibit
symptoms into adulthood. While a mainstay
of ADHD patient care, immediate-release stim-
ulant use has been constrained by concerns
about safety, tolerability, and issues related to
nonmedical use and abuse. These concerns
have prompted interest in developing modified
versions or new delivery systems for stimu-
lants. Prodrugs have been used in pharmaceu-
tical development to optimize delivery of an
active drug or to minimize toxicity. Prodrugs
are pharmacologically inactive compounds that
require in vivo conversion to release therapeu-
tically active medications. Lisdexamfetamine
FOCUS POINTS
Once-daily stimulant medications continue to
be the first-line treatment for attention-deficit/
hyperactivity disorder (ADHD).
Lisdexamfetamine dimesylate (LDX) is the first
long-acting prodrug stimulant indicated for
the treatment of ADHD. Clinical evidence sup-
ports the safety and efficacy of LDX for the
treatment of ADHD in children 6-12 years of
age and adults.
No significant cardiovascular effects or effects
on sleep quality have been observed in stud-
ies of adults taking LDX. Clinical data suggest
that LDX is generally well tolerated in children
and adults, with a safety profile consistent
with long-acting stimulant use.
dimesylate (LDX) is an inactive, water-soluble
prodrug in which d-amphetamine is bonded to
l-lysine, a naturally occurring amino acid. After
oral ingestion, LDX is metabolized into l-lysine
and active d-amphetamine. This review of LDX
presents the efficacy, safety, and pharmacoki-
netic profile of this novel stimulant medication,
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and is intended to help clinicians understand its




is a highly heritable neuropsychiatric disorder
associated with significant impairments in occu-
pational, academic, neuropsychological, and
social functioning.1 ADHD is commonly diag-
nosed in children and adolescents, and affects 3%
to 7% of children in the United States.23 Children
with ADHD may experience significant social,
emotional, and academic problems, including
low self-esteem, poor peer relationships, delin-
quency, and substance abuse. Evidence shows
that ADHD often runs in families, with a herita-
bility of 76%.2A Children and adolescents with
ADHD often present with comorbid psychiatric
disorders, including major depression, anxiety
disorders, conduct disorder, and oppositional
defiant disorder.5 ADHD in adolescents is also
associated with suboptimal academic achieve-
ment and a greater use of illicit drugs.5
While once thought of as a childhood disor-
der, ADHD symptoms persist into adulthood in
up to 65% of children with ADHD.6 Diagnostic
criteria for ADHD in adults are still based on the
18 symptoms that were originally identified in
children with ADHD. These diagnostic symp-
toms are centered around disruptions in atten-
tion and/or hyperactivity-impulsivity that are
prevalent in children with ADHD.3 Inattention
is a key component of the behaviors associ-
ated with ADHD in both children and adults.
Adults with ADHD may present with poor time
management or a lack of attention to detail.
Patients are easily distracted, find it difficult
to concentrate, and are forgetful when faced
with tasks that they find monotonous or bor-
ing.78 Hyperactivity, while a common feature
among children with ADHD, is likely to be less
overt in adults. Rather than the constant activity
seen in children, adults are more likely to report
restlessness, difficulty sitting through meet-
ings, and a feeling of being chronically "on the
go."38 They may have a sloppy workspace and
may avoid work that is challenging or requires
a maintained focus. Patients with impulsive ten-
dencies have great difficulty waiting in line, will
interrupt conversations, may act without think-
ing, or experience emotional volatility.3-7'8
The estimated prevalence of ADHD in adults
throughout the US is ~4.4%, or 9 million adults.9
ADHD in adults is highly comorbid with mood
disorders, anxiety disorders, and substance-use
disorders (SUDs). In the National Comorbidity
Survey Replication,9 only 10.9% of adults with
ADHD were currently receiving treatment for
ADHD, although as many as 53.1% of women
and 36.5% of men were being treated for other
comorbid mental health or substance-related
disorders. Adults with ADHD frequently present
in crisis and are often initially diagnosed with
mood and anxiety disorders, temper problems,
or substance abuse. Clinicians frequently treat
the presenting crisis and miss the underlying
problems from ADHD. Untreated ADHD then
creates a pervasive pattern of repeated diffi-
culties or impairment. Continuing impairment
from ADHD may cause individuals to struggle
with academic, career, and personal goals, or
may cause significant difficulty within interper-
sonal relationships.
Functional imaging studies and cognitive neu-
roscience have focused on disruptions in brain
regions normally involved in attention/cognition,
executive function, working memory, response
inhibition, and/or reward/motivation. Structural
imaging studies have identified smaller volumes
in the frontal cortex, cerebellum, and subcortical
structures in adults and children with ADHD com-
pared with those without ADHD.1 Additionally,
neuroanatomic studies in children with ADHD
have shown delayed maturation in the prefrontal
cortex, an area known to be involved with execu-
tive function and working memory.10
UNMET NEEDS IN THE TREATMENT
OF ADHD
Pharmacotherapy continues to be the main-
stay of treatment for ADHD.2 All US Food and
Drug Administration-approved medications for
the treatment of ADHD enhance the physiologi-
cal effects of either norepinephrine, dopamine,
or both. ADHD stimulants are all derived from
various preparations of either methylphenidate
(MPH) or amphetamines. MPH is felt to exert
its clinical effect by blocking the reuptake of
dopamine and norepinephrine, while amphet-
amines are felt to work by both blocking reup-
take and enhancing release of dopamine and
norepinephrine. Immediate-release (IR) and
extended-release (ER) formulations of MPH,
mixed amphetamine salts (MAS-XR), and dex-
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troamphetamine are available as pharmaco-
logic treatment options.
Despite the efficacy of short-acting stimu-
lants, they can "wear off" during the day, which
may increase symptoms of inattention during
late morning or afternoon activities." Therefore,
multiple doses during the day may be required
to achieve continuous symptom management.
Generally, longer-acting ER formulations may
eliminate the need for in-school medication
administration and provide ongoing clinical effect
during the school day.12 Long-acting stimulants
have traditionally been created utilizing mechani-
cal delivery systems or beaded preparations.
Although these improved treatment options exist,
unmet therapeutic needs remain, including con-
sistent delivery of medication, adequate duration
of action, and reduced potential for abuse.
PRODRUG STIMULANT
LISDEXAMFETAMINE DIMESYLATE
Lisdexamfetamine dimesylate (LDX), the first
long-acting prodrug stimulant, is indicated for the
treatment of ADHD in children (approved in 2007)
and adults (approved in 2008).13 LDX is a therapeu-
tically inactive, water-soluble molecule. After oral
ingestion, LDX is converted to l-lysine and active
d-amphetamine (Figure 1),14 which is responsi-
ble for the therapeutic effect. LDX is thought to be
primarily absorbed intact in the small intestines
and into the portal circulation, where hydrolysis
is thought to occur by enzymatic cleavage medi-
ated by enzymes primarily found on the red blood
cells.1516 Hydrophilic drugs, such as the prodrug
LDX, are thought to be unable to permeate the
blood-brain barrier. While this specific hypothesis
has not been tested with LDX, the requirement for
enzymatic cleavage to free the d-amphetamine
FIGURE 1 .




Reprinted from Krishnan et al, 2008, with permission of SAGE
Publications.
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may help explain the consistent pharmacokinetic
parameters, the sustained duration of action, and
the decreased abuse likeability scores, which will
be detailed in the remainder of this review.
Pharmacokinetic and Formulation Studies
Nonclinical in vivo and in vitro studies have
been conducted to investigate the absorption16
and hydrolysis1516 of LDX using rodent and
human tissues. Results of these studies suggest
that absorption of LDX occurs primarily in the
small intestine and that conversion of LDX into
active d-amphetamine occurs primarily in the
blood. Intact LDX was readily absorbed through
duodenal, jejunal, and ileal intestinal segments,
and underwent presystemic enzymatic conver-
sion to active d-amphetamine in rodents.16 LDX
was converted to amphetamine in the presence
of rat and human whole blood, but conversion
did not occur in plasma or human white blood
cells or platelets.1516 In vitro studies of enzymatic
conversion by human blood cell fractions dem-
onstrated that LDX was converted into active d-
amphetamine by red blood cells.1516
In an open-label study,17 six healthy adult vol-
unteers 22-52 years of age were administered
a single oral 70 mg dose of 14C-radiolabelled
LDX in solution following a fast of at least 10
hours. Blood samples were drawn predose
and at time points up to 120 hours postdose.
Plasma pharmacokinetic analysis was conducted
for active d-amphetamine and the intact par-
ent compound, LDX. Analysis showed LDX to
be quickly absorbed and extensively converted
to d-amphetamine. Systemic exposure to d-
amphetamine was ~20-fold higher than systemic
exposure to intact LDX, which exhibited rapid
elimination with a mean apparent terminal elimi-
nation half-life of 0.47 hours.17 Urinary excre-
tion was the predominant route of elimination of
radioactivity, with -96% of the oral dose radio-
activity recovered in the urine over a period of
120 hours. Of the radioactivity recovered in the
urine, 41.5% of the dose was related to amphet-
amine, 24.8% to hippuric acid, and 2.2% to intact
LDX. Plasma concentrations of unconverted LDX
were low and transient, generally becoming non-
quantifiable by 8 hours after administration.17
Shojaei and colleagues18 reported that the
absorption of LDX to d-amphetamine was not
affected by pH in an in vitro study. Krishnan and
Zhang14 reported the results of a randomized,
open-label, three-period crossover study of 18
CNS Spectr 15:5 317 May 20,10
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healthy adult volunteers. A single LDX dose of
70 mg was administered to each subject under
three conditions: fasting, a solution containing
the capsule contents, and an intact capsule after
a high-fat meal. The results demonstrated that
systemic exposure to d-amphetamine was bio-
equivalent when administered with or without
food or in solution. This finding suggests that
LDX is not likely to be affected by changes in
gastrointestinal transit times.14
LDX, unlike other currently approved long-
acting stimulant formulations, does not rely on
encapsulated matrix or beaded formulations
to prolong the absorption period of the active
drug.19 MAS-XR is an example of a mechanically
formulated capsule that contains two types of
drug-containing beads; one bead designed to
be released immediately and the other to be
released in the lower intestine, where pH lev-
els are higher.20 This formulation creates a pH-
dependent delivery system designed to give a
double-pulsed delivery of amphetamine, which
prolongs the release of the medication.20 Using
this technology, consistent drug delivery may be
compromised by alterations in gastric pH due to
coadministration with proton pump inhibitors.21
When compared with MAS-XR, LDX pharma-
cokinetics were significantly more consistent
when coadministered with the proton pump
inhibitor omeprazole.21 Regarding other drug-
drug interactions, d-amphetamine, the active
ingredient in LDX, is known to inhibit monoamine
oxidase.13 The ability of d-amphetamine and its
metabolites to inhibit varjous cytochrome P450
(CYP) isozymes and other enzymes has not been
adequately elucidated. In vitro experiments with
human microsomes indicate minor inhibition
of CYP2D6 by amphetamine and minor inhibi-
tion of CYP1A2, 2D6, and 3A4 by one or more
metabolites, but there are no in vivo studies of
CYP enzyme inhibition.13 In a study22 conducted to
analyze potential inhibitory drug-drug interactions
with the seven major CYP isoforms using pooled
human liver microsomes, neither concentration-
dependent nor mechanism-based inhibition of
human CYP isoforms was demonstrated for LDX
during in vitro testing.
LDX has predictable pharmacokinetic char-
acteristics. Three published studies23 26 have
examined the pharmacokinetic variability and
dose proportionality of LDX. Biederman and
colleagues23 compared the interpatient phar-
macokinetic variability of d-amphetamine after
administration of LDX (30, 50, or 70 mg/day) and
MAS-XR (10, 20, or 30 mg/day) in children with a
primary diagnosis of ADHD. LDX demonstrated
considerably lower interpatient variability of phar-
macokinetic measures compared with MAS-XR,
indicating consistent d-amphetamine pharmaco-
kinetics between patients. For example, the mean
maximum observed drug concentration (Cmax)
values for d-amphetamine following MAS-XR (30
mg) or LDX (70 mg) administration were 119±52.5
ng/mL and 155±31.4 ng/mL, respectively (Figure
2)23,24 A S measured by coefficient of variance,
the interpatient variability of Cmax following LDX
administration was lower than that observed fol-
lowing MAS-XR administration (20.34 ng/mL and
43.96 ng/mL, respectively), indicating that LDX
may provide more consistent drug delivery.23 A
further pharmacokinetic study of healthy adults
confirmed low interpatient variability in pharma-
cokinetic values and also demonstrated low intra-
patient variability in values when measured over
all doses within individual subjects.26
Efficacy Studies
The efficacy of LDX for the treatment of ADHD
has been demonstrated in three controlled clinical
trials232627 and two open-label trials2829 in children,
as well as two randomized, controlled trials3031
and one open-label trial32 in adults (Table).
Studies in Children
Biederman and colleagues23 conducted a mul-
ticenter, randomized, double-blind, placebo-con-
trolled, analog classroom crossover study of 52
children 6-12 years of age with ADHD. After 3
FIGURE 2 .
Time to peak plasma d-amphetamine
concentration in individual patients
following LDX (70 mg) and MAS-XR







LDX (70 mg) (n=8)
MAS-XR (30 mg)(n=9l
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LDX=lisdexamfetamine dimesylate; MAS-XR=mixed amphetamine salts
extended-release.
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weeks of open-label dose adjustment and opti-
mization with 10, 20, or 30 mg/day of MAS-XR,
the children received, in randomized order, 1
week each of their optimized dose of MAS-XR,
an approximately equivalent dose of 30, 50, or
70 mg of LDX, and placebo.23 The primary effi-
cacy measure was the Swanson, Kotkin, Agler,
M-Flynn, and Pelham (SKAMP)-Deportment33 rat-
ing scale. Secondary efficacy measures included
the Permanent Product Measure of Performance
(PERMP)34 derived measures and the Clinical
Global Impressions (CGI) scale.35 Treatment with
LDX and MAS-XR significantly improved mea-
sures of efficacy on the SKAMP-Deportment and
PERMP-Attempted (both P<.0001) scales. A post-
hoc analysis36 showed that at 12 hours postdose,
LDX produced significantly greater improve-
ment compared with MAS-XR on both PERMP-
Attempted and PERMP-Correct measures (P<.05;
Figure 3).2336 On the CGI scale, ratings of very
much improved or improved were noted in 74%
of children who received LDX and 72% of chil-
dren who received MAS-XR versus .18% of those
who received placebo.23 Additionally, CGI ratings
of very much improved were noted in 32% of
children who received LDX and 16% of children
who received MAS-XR versus 2% of those who
received placebo.37
Biederman and colleagues26 also conducted
a double-blind, multicenter, placebo-controlled,
parallel-group study in 290 children (6-12 years
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Children were randomly assigned to receive
LDX (30, 50, or 70 mg/day) with forced dose
titration or placebo for 4 weeks. Efficacy was
assessed using the ADHD Rating Scale Version
IV (ADHD-RS-IV),38 the Conners' Parent Rating
Scale (CPRS),39 and the CGI; tolerability was also
assessed throughout the study. Significantly
greater improvements in ADHD-RS-IV scores
were seen with each of the three LDX doses
throughout the day compared with placebo
(P<.001 for all comparisons).26 The effect sizes of
treatment with LDX were 1.39, 1.42, and 1.73 for
30, 50, and 70 mg/day of LDX, respectively.40 LDX
showed similar significant improvements in both
the inattention and hyperactivity subscales of the
ADHD-RS-IV. Using the CPRS at home, parents
of patients in each LDX dose group reported sig-
nificantly greater improvements in symptom
control throughout the day (morning, ~10 AM;
afternoon, ~2 PM; evening, ~6 PM). Compared
with placebo (18%), CGI-lmprovement (CGI-I) rat-
ings of very much improved or much improved
were seen in 2=70% of children receiving LDX.26
Wigal and colleagues27 evaluated the efficacy
of LDX in 129 school-aged children with ADHD
in a 6 week, randomized, double-blind, placebo-
controlled, analog classroom crossover study.
Significant improvements on SKAMP-Deportment
scores, the primary efficacy measure, were noted
in the active treatment group compared with pla-
FIGURE 3.
Change in children's PERMP scores
over 12 hours2336
-•-LDX -•-MAS-XR - e - Placebo
t • , t
E 1 2 3 45 6 8 10 12 1 2 3 4.5 6 8 10 12
Postdose (hours)
* P<.0001 vs placebo; N=50.
 y
t P<.0001 vs placebo and P<.05 LDX vs MAS-XR.
Study was not designed to compare LDX and MAS-XR groups.
Adapted from Biederman et al, 2007,23 with permission from Elsevier, and
Lopez et al, 2008.3B
PERMP^Permanent Product Measure of Performance; LS=least squares;
LDX=lisdexamfetamine dimesylate; MAS-XR=mixed amphetamine salts
extended-release.
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cebo (P<.005) beginning at 1.5 hours postdose
and persisting up to and including 13 hours.27
Findling and colleagues28 conducted a 12
month, open-label study to determine the long-
term efficacy of LDX in children. The intent-to-
treat (ITT) population included 272 children 6-12
years of age with previously diagnosed ADHD,
some of whom may have received LDX dur-
ing a prior study.23-2628 After a 1 week screening
period and a 1 week washout period, subjects
were titrated to 30, 50, or 70 mg/day of LDX over
4 weeks and then placed on a maintenance dose
for 11 months. Week 4 reductions in the ADHD-RS-
IV total score were maintained throughout the 12
month treatment period (Figure 4).28 At endpoint,
the ADHD-RS-IV total score change from baseline
was -27.2 points (>60% reduction; P<.0001).28
Findling and colleagues29 also conducted an
open-label, 7 week, dose-optimization study of
daily LDX doses up to 70 mg in 318 children 6-12
years of age with ADHD. Subjects were dosed
to optimal symptom response and tolerability.
The primary efficacy assessment was the ADHD-
RS-IV, and secondary assessments included the
CGI-I and the Parent Global Assessment (PGA).
Because symptoms of ADHD in children are
often accompanied by deficits in executive func-
tioning and abnormalities in emotional expres-
sion,4142 additional secondary measures included
the Expression and Emotion Scale for Children
(EESC)43 and the Behavior Rating Inventory of
Executive Function (BRIEF)-Parent Form.44 At
FIGURE 4 .
Children's ADHD-RS-IV average by
each month of treatment28*
N=270 270 263 259 251 243 222 204 193 190 172 165 158 156 150 146 270
Month of Treatment
* Results at each time point are reported for all subjects participating at
that time point (n). Results at endpoint are last-observation-carried-for-
ward results for the intent-to-treat population.
t P<.0001; paired t-test.
Used with permission from Findling et al, 2008.28
ADHD-RS-IV=Attention-DeficitfHyperactivity Disorder Rating Scale Version IV.
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endpoint, the mean change in ADHD-RS-IV total
scores from baseline was significant (P<.0001),29
By weeks 2-3 of the study, most subjects showed
improvement by clinician-rated CGI-I and par-
ent-rated PGA. Also at endpoint, the mean EESC
total and subscale scores and the BRIEF Global
Executive Composite scores were significantly
improved. Overall, LDX was effective as rated by
both investigator and parental assessment.29
Studies in Adults
Adler and colleagues30 evaluated the efficacy
of LDX in 420 adults with moderate-to-severe
ADHD. The study was a randomized, double-
blind, placebo-controlled, parallel-group, 4 week
study with forced dose escalations. After a 7-28
day washout period, patients received 30, 50,
or 70 mg/day of LDX or placebo for 4 weeks.
Baseline symptom severity as measured by
ADHD-RS-IV with adult prompts ranged from
39.4 (placebo) to 41.1 (LDX groups).30 Treatment
with LDX at all three doses was significantly
more effective than placebo, with a mean reduc-
tion in ADHD-RS-IV scores of 16.2-18.6 points in
the active treatment groups compared with 8.2
after placebo (P<.0001 versus placebo).
Significant changes in ADHD-RS-IV scores
(P<.001) were observed after the first week of
LDX treatment and continued at each postbase-
line visit (Figure 5).30 Each week during the dose
titration period, a significantly greater proportion
of subjects in each active treatment group had
a reduction in ADHD-RS-IV total score of s30%
(P<.01). Treatment effect sizes at endpoint ver-
sus placebo, calculated using mean changes in
FIGURE 5.
Change from baseline in adult ADHD-
RS-IV scores in the intent-to-treat
population30
Endpoint
* P<.0001 vs placebo; t P<001 vs placebo.
Reprinted by permission from Adler et al, 2008.30 Copyright 2008, Physicians
Postgraduate Press.
ADHD-RS-IV=Attention-Deficit/Hyperactivity Disorder Rating Scale
Version IV; LS=least squares; LDX=lisdexamfetamine dimesylate.
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ADHD-RS-IV scores, were 0.73, 0.89, and 0.99 for
the 30, 50, and 70 mg groups, respectively.30 The
investigators also measured the efficacy of LDX
using the CGI-I scale. On this scale, the percent-
ages of adults taking LDX rated by investigators
as improved or very much improved at endpoint
were 57% (30 mg), 62% (50 mg), and 61% (70 mg),
significantly more (P<.01) than with placebo.30
In a separate presentation of the short-term
adult data,30 Adler and colleagues45 analyzed the
effect of LDX on sleep quality using the Pittsburgh
Sleep Quality Index (PSQI). At baseline, patients
with ADHD generally had global PSQI scores >5,
suggesting that they were poor sleepers. LDX
was not associated with statistically significant
changes in overall sleep quality.45
Additional post hoc subpopulation analyses46
of these adult data30 revealed that LDX treatment
was effective and generally well tolerated in 36
patients with a history of depression or mood
disorders not currently requiring treatment with
antidepressants. LDX produced similar improve-
ments in ADHD-RS-IV and CGI-I scores in those
with and without a history of depressive disor-
ders.46 In another exploratory post hoc analy-
sis,47 LDX produced similar improvements in
ADHD-RS-IV and CGI-I scores in subjects with
and without a history of SUD. Lastly, when the
data were assessed as a function of gender,48
LDX treatment produced significant improve-
ments in ADHD-RS-IV scores for both male and
female subjects when compared with same-sex
subjects treated with placebo.
The efficacy and duration of effect of LDX in
adults with ADHD have also been assessed in a
randomized, double-blind, placebo-controlled
crossover study31 in a simulated workplace envi-
ronment. Three doses of LDX (30, 50, and 70 mg)
were compared with placebo in 142 adults with
ADHD. When compared with those given placebo,
patients treated with LDX demonstrated significant
improvement in average total PERMP scores (289.5
and 312.9, respectively; P<.0001) and significantly
better mean PERMP total scores at each postdose
assessment from 2-14 hours (P<.01 for all).31
Long-term LDX treatment efficacy in adults
was evaluated in a 12 month, open-label, sin-
gle-arm, long-term extension study32 of LDX
30, 50, or 70 mg/day for 4 weeks, and then con-
tinued for 11 months with dose adjustments
made as necessary. Patients treated with LDX
showed significant improvements in ADHD-
RS-IV total scores relative to baseline at all vis-
CNS Spectr 15:5 321 May 2010
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its, beginning as early as week 1.32 At endpoint,
84% of patients had CGI-I scores showing
improvement relative to baseline, indicating
that LDX efficacy was sustained throughout
the year. LDX treatment was also associated
with statistically significant improvements in
global PSQI scores.32
Safety and Tolerability Studies
In the multicenter, randomized, double-blind,
placebo-controlled, analog classroom crossover
study23 of 52 children 6-12 years of age with
ADHD, the most common adverse events (inci-
dence >2%) in children who took LDX included
insomnia, decreased appetite, and anorexia.
In the double-blind, multicenter, placebo-con-
trolled, parallel-group study26 of 290 children
6-12 years of age with a primary diagnosis of
ADHD, most adverse events were mild to mod-
erate and occurred during the first week; these
included decreased appetite, insomnia, upper
abdominal pain, headache, irritability, vomit-
ing, weight loss, and nausea. In the 6 week,
randomized, double-blind, placebo-controlled,
analog classroom crossover study27 of LDX in
129 school-aged children with ADHD, small mean
increases in blood pressure and small weight
reductions consistent with the known effects of
stimulant use were observed.
LDX was well tolerated during the 12 month
duration of the open-label study28 of 272 chil-
dren 6-12 years of age with previously diag-
nosed ADHD. Most reported adverse events
(97.5%) were mild or moderate in severity. Of
the adverse events with a >5% incidence, most
occurred within the first 4 weeks of treatment.
Insomnia and vomiting were seen at a higher
incidence in patients who received higher doses
of LDX (17% for 70 mg/day, 9% for 50 mg/day,
and 4% for 30 mg/day for insomnia; and 6%, 4%,
and 3% for vomiting, respectively). No patient
showed a QTc interval ;>500 msec at any treat-
ment visit and no observed abnormal electro-
cardiographic measurements were considered
clinically meaningful by the investigators.28
Lastly, in an open-label, 7 week, dose-optimiza-
tion study29 of daily LDX doses up to 70 mg in
318 children 6-12 years of age with ADHD, LDX
was generally well tolerated, with a safety profile
consistent with long-acting stimulant use.
The most common adverse events in the ran-
domized, double-blind, placebo-controlled, par-
allel-group, 4 week study30 of adults with forced
dose escalations were decreased appetite,
anorexia, insomnia, nausea, diarrhea, anxiety,
feeling jittery, and dry mouth. Analysis of the
cardiovascular effects of LDX showed no effects
on QTcF measurements or clinically meaningful
trends for systolic or diastolic blood pressure.49
During the dose-optimization phase of the dou-
ble-blind, placebo-controlled crossover study31
in a simulated workplace environment, the
most frequently reported adverse events (a5%)
for adult patients were decreased appetite, dry
mouth, headache, insomnia, upper respiratory
tract infection, irritability, nausea, anxiety, and
feeling jittery. In the 12 month, open-label, sin-
gle-arm, long-term extension study32 of LDX 30,
50, or 70 mg/day for 4 weeks, and then contin-
ued for 11 months with dose adjustments made
as necessary in adults, LDX was well tolerated;
most adverse events occurred early in treat-
ment and were of mild or moderate severity.
Subjects showed a mean increase of ~3.2 beats/
minute from baseline to endpoint. The mean
changes in systolic and diastolic blood pres-
sure from baseline to endpoint were 3.1 and 1.3
mmHg, respectively.32
Abuse-Liability Studies
LDX is currently the only FDA-approved prod-
uct for the treatment of ADHD that includes
abuse-liability data in the product label.13 In a
double-blind, placebo-controlled, abuse-liabil-
ity study,50 equivalent intravenous doses of 50
mg of LDX and 20 mg of d-amphetamine were
administered to adults without ADHD and with
a history of drug abuse. A 50 mg dose of LDX
administered intravenously did not produce
abuse-liking effects significantly different than
placebo; however, after intravenous administra-
tion of 20 mg of IR d-amphetamine, significantly
greater increases in abuse-related liking scores
were noted compared with placebo (P=.O1).50
The abuse liabilities for orally administered
50, 100, and 150 mg LDX, as well as d-amphet-
amine (40 mg), were addressed in a study51 of 36
adults with a known history of stimulant abuse.
Although the amphetamine base content of 100
mg of LDX is equivalent to that of 40 mg of d-
amphetamine, study participants reported sig-
nificantly lower mean abuse-related liking scores
with LDX 100 mg than with d-amphetamine
40 mg (Figure 6; P<.05).51 Abuse-related liking
scores of LDX at a dose corresponding to a 50%
higher amphetamine base (LDX 150 mg) were
similar to d-amphetamine 40 mg.61
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CLINICAL PLACEMENT
LDX is a long-acting prodrug, amphetamine-
based stimulant which can be used once daily for
children or adults with ADHD.13 Particular areas
where LDX is unique and may therefore be the
preferred agent include:
Coverage across the lifespan. LDX is FDA
approved and has significant efficacy at the same
dosages in both children and adults with ADHD.23-26"32
Water solubility. LDX is FDA approved to be
dissolved in water.13 When dissolved in water,
LDX maintains its sustained duration of action
and has a slightly sweet taste.
Consistent pharmacokinetics. The enzymatic
conversion of LDX into d-amphetamine is primarily
due to enzymes on the red blood cells1516 and is not
affected by changes in gastric pH or transit time.141821
Sustained duration of action. LDX has dem-
onstrated efficacy at 12 and 13 hours postdose in
pediatric clinical trails2327 and up to 14 hours in an
adult clinical trial.31 These results suggests that
LDX has the longest proven efficacy of any stimu-
lant indicated for use in the treatment of ADHD in
children or adults.
Lack of worsening of sleep quality. Sleep qual-
ity was prospectively measured in an adult LDX
clinical trial.30-45 After 4 weeks of treatment, self-
reported daytime functioning had significantly
improved for patients treated with LDX, no wors-
ening of sleep parameters was observed, and
transient insomnia, which was a common side
effect, gradually resolved in most patients.3045
Reduced potential for substance abuse. LDX
is a preferred agent for patients or families with a
FIGURE 6.
Maximum mean change in DRQS








* P<.01 vs placebo; t P<.05 vs d-amphetamine.
Reprinted from Jasinski and Krishnan, 2009,sl with permission from SAGE
Publications.
DRQS=Drug Rating Questionnaire-Subject; LDX=lisdexamfetamine dimesylate.
Mattingly G. CNS Spectr. Vol 15, No 5. 2010.
history of substance abuse. Oral or intravenous
administration of LDX has been associated with
less likeability than similar doses of d-amphet-
amine.5051 LDX cannot be ground or dissolved
into a short-acting stimulant.51
CONCLUSION
ADHD is a common neurobehavioral disor-
der that typically presents first in childhood and
often persists into adulthood, causing significant
impairments in multiple domains of function.
Treatment strategies include the use of stimu-
lant and nonstimulant medications, as well as
adjunctive cognitive-behavioral skills training and
psychotherapy. Despite a long history of proven
efficacy, the need for multiple daily doses can be
problematic for patients when using short-acting
stimulants. Additionally, concerns about the gen-
eral risk profile of stimulants have led to the need
for new, once-daily formulations that provide a
prolonged duration of action.
While long-acting stimulants are effective in
treating ADHD, increased pharmacokinetic vari-
ability may result in inconsistent efficacy both
within individual patients from day to day and
between patients. This enzymatic process by
which LDX is converted into d-amphetamine in
the blood results in very consistent pharmacoki-
netics that are less effected by gastric contents,
gastric pH, or gastrointestinal transit time than
are other long-acting stimulants. LDX requires
a physiologic enzymatic conversion and rep-
resents the first of a novel class of agents for
treating ADHD in children and adults. Clinical
evidence supports the effectiveness and tolera-
bility of LDX in adults and children. Additionally,
LDX offers the benefits of less pharmacokinetic
variability and a tolerability profile consistent
with long-acting stimulant use.
The measures used in clinical trials of LDX
reflect the DSM-IVsymptom cluster for ADHD
and demonstrate significant improvements over
placebo throughout the day. LDX was effective
in pediatric studies, with significant improve-
ments in behavior, attention, quality of work, and
number of attempted and correct math prob-
lems up to 13 hours postdose. At home, parent-
rated improvements in symptom control were
reported throughout the day up to 6 PM. In addi-
tion, robust effect sizes have been shown in both
pediatric and adult studies with LDX 30, 50, and
70 mg. Among children, there was no worsening
of mean emotional expression scores. Children
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also showed improvement in parent ratings of
executive function. Analyses of adult subjects
over 4 weeks showed no significant cardio-
vascular effects or effects on sleep quality. In
patients with a history of depression or SUD,
LDX produced similar improvements in ADHD-
RS-IV and CGI-I scores compared with subjects
who were not depressed or substance abusers.
In human abuse-liability studies, LDX produced
lower subjective drug-liking responses than
dose-equivalent IR d-amphetamine. Results
of long-term, open-label studies in children
and adults have shown LDX to be effective in
improving symptoms of ADHD over a range
of doses while being generally well tolerated,
with a safety profile consistent with long-acting
stimulant use. CNS
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